The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors was written by Hamblett, Christopher L.;Methot, Joey L.;Mampreian, Dawn M.;Sloman, David L.;Stanton, Matthew G.;Kral, Astrid M.;Fleming, Judith C.;Cruz, Jonathan C.;Chenard, Melissa;Ozerova, Nicole;Hitz, Anna M.;Wang, Hongmei;Deshmukh, Sujal V.;Nazef, Naim;Harsch, Andreas;Hughes, Bethany;Dahlberg, William K.;Szewczak, Alex A.;Middleton, Richard E.;Mosley, Ralph T.;Secrist, J. Paul;Miller, Thomas A.. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2007.Recommanded Product: 923565-99-5 This article mentions the following:
This communication highlights the development of a nicotinamide series of histone deacetylase inhibitors (e.g. I) within the benzamide structural class. Extensive exploration around the nicotinamide core led to the discovery of a class I selective HDAC inhibitor that possesses excellent intrinsic and cell-based potency, acceptable ancillary pharmacol., favorable pharmacokinetics, sustained pharmacodynamics in vitro, and achieves in vivo efficacy in an HCT116 xenograft model. In the experiment, the researchers used many compounds, for example, (R)-1-Cbz-2-methylpiperazine (cas: 923565-99-5Recommanded Product: 923565-99-5).
(R)-1-Cbz-2-methylpiperazine (cas: 923565-99-5) belongs to piperazine derivatives. Piperazine was first introduced as an anthelmintic in 1953. Piperazine compounds mediate their anthelmintic action by generally paralyzing parasites, allowing the host body to easily remove or expel the invading organism. Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successful. Recommanded Product: 923565-99-5
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics